Home >> General Pharmaceuticals >> Housing >> Food & Beverage >>

Gastroenteritis - Pipeline Review, H2 2014

Published: Dec-2014 | Format: PDF | Global Markets Direct | Number of pages: 51 | Code: MRS - 18530


Global Markets Directs, Gastroenteritis Pipeline Review, H2 2014, provides an overview of the Gastroenteritiss therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Gastroenteritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastroenteritis and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

The report provides a snapshot of the global therapeutic landscape of Gastroenteritis
The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in the therapeutics development for Gastroenteritis and enlists all their major and minor projects
The report summarizes all the dormant and discontinued pipeline projects
A review of the Gastroenteritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
A detailed assessment of monotherapy and combination therapy pipeline projects
Coverage of the Gastroenteritis pipeline on the basis of target, MoA, route of administration and molecule type
Latest news and deals relating related to pipeline products

Reasons to buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for Gastroenteritis
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding Gastroenteritis pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Content 

Table of Contents 2
List of Tables 4
List of Figures 4

Introduction 5
Global Markets Direct Report Coverage 5
Gastroenteritis Overview 6
Therapeutics Development 7
Pipeline Products for Gastroenteritis - Overview 7
Pipeline Products for Gastroenteritis - Comparative Analysis 8
Gastroenteritis - Therapeutics under Development by Companies 9
Gastroenteritis - Therapeutics under Investigation by Universities/Institutes 10
Gastroenteritis - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Gastroenteritis - Products under Development by Companies 14
Gastroenteritis - Products under Investigation by Universities/Institutes 15
Gastroenteritis - Companies Involved in Therapeutics Development 16
Bharat Biotech International Limited 16
Cocrystal Pharma, Inc. 17
RedHill Biopharma Ltd. 18
Takeda Pharmaceutical Company Limited 19
UMN Pharma Inc. 20
Gastroenteritis - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
Antibody to Target TRIM-21 for Gastrointestinal and Ear Nose Throat Disorders - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
norovirus (bivalent) vaccine - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
ondansetron hydrochloride CR - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ORV-116E - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Small Molecules to Inhibit RNA Dependent RNA Polymerase for Acute Gastroenteritis - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
UMN-2002 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
UMN-2003 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Gastroenteritis - Recent Pipeline Updates 38
Gastroenteritis - Product Development Milestones 43
Featured News & Press Releases 43
Dec 17, 2014: RedHill Biopharma Announces First Patients Enrolled in the Phase III Study of RHB-102 (BEKINDA) for Gastroenteritis and Gastritis 43
Dec 09, 2014: RedHill Biopharma Submits BEKINDA (RHB-102) European Marketing Authorization Application for Oncology Support 44
Sep 03, 2014: RedHill Biopharma Initiates Phase III Study of RHB-102 for Gastroenteritis 45
Dec 08, 2011: The New England Journal Of Medicine Publishes Study Showing LigoCyte's Norovirus Vaccine Demonstrates Protection Against Illness 46
Oct 25, 2010: LigoCyte Presents Positive Results From Norovirus Vaccine Challenge Study At IDSA Annual Meeting 48

Appendix 50
Methodology 50
Coverage 50
Secondary Research 50
Primary Research 50
Expert Panel Validation 50
Contact Us 51
Disclaimer 51

List of Tables

Number of Products under Development for Gastroenteritis, H2 2014 7
Number of Products under Development for Gastroenteritis - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Late Stage Development, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Products under Investigation by Universities/Institutes, H2 2014 15
Gastroenteritis - Pipeline by Bharat Biotech International Limited, H2 2014 16
Gastroenteritis - Pipeline by Cocrystal Pharma, Inc., H2 2014 17
Gastroenteritis - Pipeline by RedHill Biopharma Ltd., H2 2014 18
Gastroenteritis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 19
Gastroenteritis - Pipeline by UMN Pharma Inc., H2 2014 20
Assessment by Monotherapy Products, H2 2014 21
Number of Products by Stage and Target, H2 2014 23
Number of Products by Stage and Mechanism of Action, H2 2014 25
Number of Products by Stage and Route of Administration, H2 2014 27
Number of Products by Stage and Molecule Type, H2 2014 29
Gastroenteritis Therapeutics - Recent Pipeline Updates, H2 2014 38

List of Figures

Number of Products under Development for Gastroenteritis, H2 2014 7
Number of Products under Development for Gastroenteritis - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Early Stage Products, H2 2014 13
Assessment by Monotherapy Products, H2 2014 21
Number of Products by Top 10 Targets, H2 2014 22
Number of Products by Stage and Top 10 Targets, H2 2014 22
Number of Products by Top 10 Mechanism of Actions, H2 2014 24
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 24
Number of Products by Top 10 Routes of Administration, H2 2014 26
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 26
Number of Products by Top 10 Molecule Types, H2 2014 28
Number of Products by Stage and Top 10 Molecule Types, H2 2014 28

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing